BRIEFLY
- COOPER COMPANIES COMPLETES MERGER
WITH OCULAR SCIENCES. The Cooper
Companies, Inc., recently announced that its merger with Ocular Sciences,
Inc., has been completed. At closing, Cooper paid approximately $600
million in cash and issued approximately 10.7 million shares of its
common stock to Ocular Sciences stockholders and option holders. The
Cooper Companies" CooperVision unit, the world"s fourth-largest contact
lens manufacturer, is a leading global supplier of specialty contact
lenses. Ocular Sciences, the world"s fifth-largest contact lens manufacturer,
supplies primarily spherical and daily disposable contact lenses.
With the completion of the merger, CooperVision becomes the world"s
third-largest contact lens company.
- GENAERAS
SQUALAMINE CHOSEN FOR FDA CMA PILOT 2 PROGRAM. The FDA
has selected squalamine, Genaera Corporations systemically administered
anti-angiogenic small molecule, for participation in its Continuous
Marketing Application (CMA) Pilot 2 program. Genaera is developing
squalamine for the treatment of wet age-related macular degeneration
(AMD); it is currently undergoing three Phase II trials for treatment
of AMD at multiple sites throughout the United States. Participation
in the Pilot 2 program is limited to only one Fast Track product for
each review division within the Center for Drug Evaluation and Research
(CDER) and the Center for Biologics Evaluation and Research (CBER).
Squalamine was selected by CDER"s Division of Anti-Inflammatory, Analgesic
and Ophthalmic Drug Products. In October 2004, the FDA granted it
Fast Track status. The CMA Pilot 2 program provides for frequent scientific
feedback and interactions during the Investigational New Drug phase
of development, based on a defined agreement between the FDA and the
applicant. The FDA initiated the CMA Pilot 2 program to evaluate the
costs and benefits of increased sponsor access to guidance and feedback
from the FDA for Fast Track products. For information about participation
in squalamine clinical trials, call Genaera"s Clinical Trial Hotline
at 800-299-9156.
- ALLABOUTVISION.COM TRAFFIC UP 50
PERCENT IN 2004. Growing consumer demand for online eye
health and vision correction information boosted visitor traffic on
AllAboutVision.com
by 50 percent in 2004, according to the companys publisher,
Tom Meinert. LASIK and eye conditions including glaucoma, macular
degeneration, astigmatism and cataracts were among the most popular
topics for the more than 4.8 million unique visitors to the site.
Citings in the Wall Street Journal and Newsweek also
contributed to traffic growth. Online since January 2000, AllAboutVision.com
provides consumers with more than 450 pages of up-to-date doctor-reviewed
content. The site is published by Access Media Group, LLC, a print
and electronic communications company specializing in vision care.
For more information, contact Ron Walker at 610-492-1033 or go to
www.AllAboutVision.com/prof/.
- COLLAGEN MATRIX DEVELOPED TO PREVENT
SCAR FORMATION IN GLAUCOMA FILTRATION MICROSURGERY. The
Pro Top and Mediking Companies of Taiwan recently announced that they
have successfully developed a scarring inhibitor for glaucoma filtration
microsurgery and other ophthalmic surgical procedures. The inhibitor,
called OculusGen, is a biodegradable, three-dimensional, porous collagen-glycosaminoglican
scaffold that helps prevent scar formation and creates a physiological
aqua buffer environment for modulating the trabeculectomy and other
ophthalmic surgeries, including pterygium, ocular plastic, strabismus
correction, conjunctiva scar removal, orbital and nasolacrimal duct
surgery. OculusGen was developed and patented by Life Spring Biotechnology
Company Limited. Pro Top and Mediking are processing an application
for the CE Mark for OculusGen, and they expect to attain the mark
before summer 2005. For more information, go to www.OculusGen.com.
|